Department of Lifestyle Medicine
Created in 2008, the department of lifestyle medicine at the Tohoku University provides the new insights into the regulation of lifestyle and lifestyle-related metabolic diseases. Since 1998, Dr. Nonogaki et al., have found that serotonin 5-HT2C receptor is a target of drug discovery for the age-associated obesity and type 2 diabetes. In May 2012, US FDA approved Belviq (lorcaserin), the selective 5-HT2C receptor agonist, as a new anti-obesity agent.
Current work is focused on the 5-HT-peptide network, novel signaling of satiety other than 5-HT2C receptor-melanocortin pathways, and gut-brain-liver network in the regulation of hepatic glucose production. Moreover, we are under development of novel medical devices, which will be available for the treatment of lifestyle-related health problems.
Contact Information
Katsunori Nonogaki MD, PhD
Professor, Department of Lifestyle Medicine
Translational Research Center, Tohoku University Hospital
1-1 Seiryo-machi, Aoba,
Sendai, Miyagi, Japan 980-8574
022-717-7061 (phone&FAX)
knonogaki-tky@umin.ac.jp
Katsunori Nonogaki, MD, PhD